Azapropazone
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB07402 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 31 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | acromesomelic dysplasia, Hunter-Thompson type | KG + DL |
| 2 | brachyolmia-amelogenesis imperfecta syndrome | KG + DL |
| 3 | myosclerosis | KG + DL |
| 4 | pseudoachondroplasia | KG + DL |
| 5 | brachyolmia | KG + DL |
| 6 | rheumatoid vasculitis | KG + DL |
| 7 | hypermobility of coccyx | KG + DL |
| 8 | polyarticular juvenile rheumatoid arthritis | KG + DL |
| 9 | Kummell disease | KG + DL |
| 10 | inflammatory spondylopathy | KG + DL |
| 11 | vertebral disease | KG + DL |
| 12 | colobomatous microphthalmia-rhizomelic dysplasia syndrome | KG + DL |
| 13 | heparin cofactor 2 deficiency | KG + DL |
| 14 | brachydactyly-syndactyly syndrome | KG + DL |
| 15 | rheumatoid nodulosis | KG + DL |
| 16 | rheumatoid factor-positive polyarticular juvenile idiopathic arthritis | KG + DL |
| 17 | juvenile idiopathic arthritis | KG + DL |
| 18 | juvenile chronic polyarthritis | KG + DL |
| 19 | factor 5 excess with spontaneous thrombosis | KG + DL |
| 20 | WHIM syndrome | KG + DL |
| 21 | antithrombin deficiency type 2 | KG + DL |
| 22 | juvenile arthritis due to defect in LACC1 | KG + DL |
| 23 | mendelian susceptibility to mycobacterial diseases due to complete IL12B deficiency | KG + DL |
| 24 | combined immunodeficiency due to moesin deficiency | KG + DL |
| 25 | thrombophilia | KG + DL |
| 26 | spondyloarthropathy | KG + DL |
| 27 | fibroma | KG + DL |
| 28 | gingival hypertrophy | KG + DL |
| 29 | leukoplakia | KG + DL |
| 30 | infantile systemic hyalinosis | KG + DL |
| 31 | avascular necrosis of femoral head, primary | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.